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Designing non-natural antibody formats is a practical method for developing highly functional next-
generation antibody drugs, particularly for improving the therapeutic efficacy of cancer treatments. 
One approach is constructing bispecific antibodies (bsAbs). We previously reported a functional 
humanized bispecific diabody (bsDb) that targeted epidermal growth factor receptor and CD3 
(hEx3-Db). We enhanced its cytotoxicity by constructing an Fc fusion protein and rearranging order 
of the V domain. In this study, we created an additional functional bsAb, by integrating the molecular 
formats of bsAb and high-affinity mutants previously isolated by phage display in the form of Fv. 
Introducing the high-affinity mutations into bsDbs successfully increased their affinities and enhanced 
their cytotoxicity in vitro and in vivo. However, there were some limitations to affinity maturation of 
bsDb by integrating high-affinity Fv mutants, particularly in Fc-fused bsDb with intrinsic high affinity, 
because of their bivalency. The tetramers fractionated from the bsDb mutant exhibited the highest in 
vitro growth inhibition among the small bsAbs and was comparable to the in vivo anti-tumor effects of 
Fc-fused bsDbs. This molecule shows cost-efficient bacterial production and high therapeutic potential.
Conventional monoclonal antibodies have been widely used to treat diseases with difficulties to cure such as 
rheumatism1,2. However, particularly in the field of cancer treatments, animal and clinical studies have high-
lighted the limitations of therapeutic efficacy of monoclonal antibodies3. Therefore, many strategies for improving 
the function of antibodies have been explored; one such strategy is the design of non-natural antibody formats, 
particularly bispecific antibodies (bsAbs) and antibody fusion proteins, such as immunotoxins. The United States 
Food and Drug Administration (FDA) has only approved two non-natural antibody designs to treat cancer: 
blinatumomab in 20093 and moxetumomab pasudotox in 20184. Thus, additional studies are needed to produce 
next-generation antibody drugs with high therapeutic potential.
BsAbs have ability to simultaneously bind two different targets. For example, bsAbs can redirect various 
immune cells, mainly cytotoxic T cells and natural killer cells, toward cancer cells. The difficulty in mass produc-
tion of homogeneous bsAbs using traditional techniques, hybrid hybridomas and chemical cross-linking, has 
limited their wider application as therapeutic reagents5; however, advanced design of formats have facilitated the 
production of homogeneous bsAbs. Numerous bsAb formats, ranging from IgG-like molecules to small mole-
cules, such as diabodies (Dbs)6, single-chain Dbs (scDbs)7, tandem single-chain variable fragments8, and other 
derivatives9, have been reported. Some of these small bsAb formats can be produced in bacterial expression 
systems and are used as building blocks to design more functional molecular formats, such as that of the human 
Fc fusion10.
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We previously developed a bsAb and constructed a functional humanized bsDb that targets epidermal growth 
factor receptor (EGFR) and CD3 (hEx3-HL) (Fig. 1A)11. We also reported the substantial intense cancer growth 
inhibition effects of fractionated bsDb tetramers that emerged during the preparation of hEx3-HL (Fig. 1B)12. 
Further, marked enhancement in the cytotoxicity of hEx3-HL was achieved by rearranging the domain order of 
the V domain, particularly LH type (hEx3-LH) (Fig. 1C,D), in which both components were in the VL-VH order 
and exerted the strongest anti-tumor activity13. Finally, using bsDbs as building blocks, we generated their Fc 
fusion formats and confirmed any additional enhanced effects (Fig. 1E,F)14,15. In contrast, affinity maturation is an 
important strategy for improving antibody function. In fact, reductions in the affinity of anti-EGFR antibody 528, 
used in our study were observed after humanization of the antibody16. Thus, we isolated high-affinity humanized 
528 (h528) VH mutants using a phage display method; and increased cancer growth inhibition was observed by 
integrating these mutants into hEx3-HL17. However, we have not applied the approaches used to design hEx3-HL, 
in other functional bsAb formats. Further, we recently isolated high-affinity h528 VL mutants18.
Here, to create additional functional bsAbs, we integrated the high-affinity h528 VH and VL mutants into 
hEx3-LH and Fc-fused hEx3-Dbs. The affinity of hEx3-LH was successfully improved by introducing muta-
tions, which enhanced the cytotoxicity of the bsAbs in vitro and in vivo. However, there were some limitations 
to the affinity maturation of bsDb caused by integrating mutants isolated in the Fv form. In Fc-fused hEx3-Dbs, 
introducing mutations enhanced in vitro cytotoxicity, but not in vivo. Although a more sensitive in vivo model 
is needed to evaluate these molecules, we successfully developed a highly potent small bsDb by integrating a 
high-affinity mutant; particularly, the hEx3-LH mutant tetramer showed comparable in vivo therapeutic effects 
to Fc-fused hEx3-Dbs.
Figure 1. Schematic diagrams of bsAb formats evaluated in this study. Bispecific diabody that targets epidermal 
growth factor receptor and CD3 (a) and its tetramer that emerged during the preparation (b), domain order 
rearranged format, in which both components were in the VL-VH order (c,d), and Fc fusion formats (e,f).
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Results
Preparation of hEx3-LH mutants and evaluation of affinity. To improve the function of hEx3-LH, 
we integrated it with high-affinity mutants and evaluated the affinity of the modified antibodies. We recovered the 
reductions in the affinity of 528 caused by humanization using phage display and isolated high-affinity mutants. 
First, we isolated a single h528 VH mutant, HY52W, and then obtained a higher affinity mutant, 2HH11, with 
three additional mutations compared to those of HY52W17. Finally, based on 2HH11, we isolated much higher 
affinity h528 VL mutants, 2L1 and 2L6 that contain three and two mutated residues, respectively18. Here, we 
integrated the mutants into hEx3-LH and prepared dimers using the Escherichia coli expression system described 
in the Materials and Methods. To investigate the interaction between soluble EGFR (sEGFR) and hEx3-LH 
mutants, we determined the binding kinetics using immobilized sEGFR and surface plasmon resonance (SPR) 
spectroscopy (Table 1). Increased affinity was observed in LH-HY52W; however, additional improvements were 
not observed with the other hEx3-LH mutants, although higher affinity mutants of h528 Fv (2HH11, 2HH11-2L1, 
and 2HH11-2L6) were used in their construction. The affinity of hEx3-LH was improved, but it was found some 
limitation in increasing affinity through integrating mutants isolated in the Fv form.
Effects of mutations in hEx3-LH on cancer growth inhibition. To evaluate the influence of the 
increase in affinity, mediated by the mutations, on the inhibition of human carcinoma cell growth, we analyzed 
the four fractionated hEx3-LH mutant dimers in cell proliferation colorimetric assays. Enhanced cytotoxicity 
was observed for LH-HY52W (Fig. 2A); introduction of a single mutation effectively improved the function of 
hEx3-LH. However, consistent with the results of affinity evaluation, hEx3-LH mutants with additional muta-
tions in LH-HY52W did not show improvement (Fig. 2A–C). The hEx3-LH mutants showed comparable effects 
to E2x3-LH (Fig. 2C), which was previously reported to have greater effects than hEx3-LH, but contains mouse 
anti-EGFR sequences unlike hEx3-LH19. We also observed the cancer growth inhibition effects of fraction-
ated bsDb tetramers during the preparation of Db12. Here, we fractionated the tetramer of LH-HY52W, and as 
expected it had the highest cytotoxicity (Fig. 2D,E). These results demonstrate that introducing a high-affinity 
single point mutation enhances the cytotoxicity of hEx3-LH.
Preparation and functional evaluation of Fc-fused hEx3-Db. To create more functional bsAbs, 
we integrated high-affinity mutants into Fc-fused hEx3-Db, Fc-HL, and Fc-LH and prepared monomers using 
the Chinese hamster ovary (CHO) expression system as described in the Materials and Methods. Affinity was 
increased by introducing mutations according to SPR analysis; however, reliable kinetic values were not obtained 
because the intrinsic affinity of Fc-fused bsDbs is high, since the avidity effects caused by bivalent binding exceeds 
the limit of detection of the instrument. To evaluate the growth inhibition effects of Fc-fused hEx3-Db mutants, 
we analyzed cell proliferation in colorimetric assays as conducted for hEx3-Dbs. Introduction of the HY52W 
mutation also increased the cytotoxicity of both Fc-HL and Fc-LH (Fig. 3A). For Fc-LH, Fc-LH-2HH11 showed 
a slight further improvement compared to Fc-LH-HY52W (Fig. 3B). The cytotoxicity in the presence of unstim-
ulated peripheral blood mononuclear cells (PBMCs) is important when considering the therapeutic potential of 
bsAbs. When PBMCs were used as effector cells, Fc-LH-2HH11 also inhibited cancer cell growth effectively, but 
further improvements were not observed when additional high-affinity VL mutants, Fc-LH-2HH11-2L1 and 
Fc-LH-2HH11-2L6, were integrated (Fig. 3C).
In vivo antitumor effects of hEx3-LH mutants. To compare in vivo antitumor effects of the 
hEx3-LH and hEx3-LH mutants, we transplanted mixtures of human bile duct carcinoma (TFK-1) cells and 
lymphokine-activated killer cells with the T-cell phenotype (T-LAK) cells into severe combined immunode-
ficient (SCID) mice, which were then treated for four days with bsDbs. Compared to the phosphate-buffered 
saline (PBS) controls, treatment with 2 µg of hEx3-LH markedly inhibited tumor growth in SCID mice; however, 
0.2 µg of hEx3-LH showed only moderate growth inhibitory effects (Fig. 4A). In contrast, 0.2 µg of hEx3-LH 
mutants still inhibited tumor growth effectively (Fig. 4A,B). Consistent with the in vitro results, hEx3-LH mutant 
(2HH11-2L1) showed comparable effects to E2x3-LH (Fig. 4A), and there were no major differences between 
hEx3-LH mutants with additional mutations in LH-HY52W (2HH11 and 2HH11-2L6) (Fig. 4B). Even at a dose 
of 0.02 µg, in which hEx3-LH mutants only exhibited moderate antitumor effects, the LH-HY52W tetramer 
inhibited tumor growth; this effect was greatly reduced at a dose of 0.002 µg (Fig. 4C). These results demonstrate 
that the high-affinity mutations inhibited tumor growth in an in vivo tumor model.
sEGFR
kon (×105 M−1s−1) koff (×10−3 s–1) KA (×107 M−1)
hEx3-HL 0.93 2.0 4.6a
hEx3-LH 0.73 3.6 2.0a
LH-HY52W 2.2 0.64 34
LH-2HH11 1.4 0.50 29
LH-2HH11-2L1 2.4 0.56 43
LH-2HH11-2L6 2.6 0.65 41
E2x3-LH 8.2 4.3 19a
Table 1. Binding parameters of bsDbs. aData from our previous report19.
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In vivo antitumor effects of Fc-fused hEx3-Db. To evaluate the in vivo antitumor activity of Fc-fused 
hEx3-Db mutants, we used the transplanted mouse model used to examine the hEx3-LH mutants. Although 
0.02 µg of both LH-Fc and LH-Fc-HY52W markedly inhibited tumor growth in SCID mice (Fig. 5A), none of the 
Figure 2. Growth inhibition of epidermal growth factor receptor (EGFR)-positive TFK-1 cells by each 
bispecific diabody (bsDb). Lymphokine-activated killer cells with T-cell phenotype (T-LAK) cells were 
added to cancer cells at a ratio of 2.5:1 (B,C) and 5:1 (A,D,E). Data are presented as the mean ± 1 SD and are 
representative of at least two independent experiments. *, Significant (P < 0.05) difference between LH-HY52W 
and hEx3-LH (A,D), and LH-HY52W tetramer and LH-HY52W (E). Statistical analysis was carried out using 
the Student’s t test.
Figure 3. Growth inhibition of epidermal growth factor receptor (EGFR)-positive TFK-1 cells by each Fc-fused 
bispecific diabody (bsDb). Lymphokine-activated killer cells with T-cell phenotype (T-LAK) cells were added 
to TFK-1 cells at a ratio of 5:1 (A) and 3:1 (B). Peripheral blood mononuclear cells (PBMCs) were added to 
TFK-1 cells at a ratio of 40:1 (C). Data are presented as the mean ± 1 SD and are representative of at least two 
independent experiments. *Significant (P < 0.05) difference between Fc-HL-HY52W and Fc-HL, and Fc-LH-
HY52W and Fc-LH (A), Fc-LH-2HH11 and Fc-LH-HY52W (B). Statistical analysis was carried out using the 
Student’s t test.
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LH-Fc mutants tested and 0.002 µg LH-Fc showed intense antitumor effects (Fig. 5B). In the in vivo tumor models 
used in this study, further enhancements in antitumor effects were not observed by introducing high-affinity 
mutation. Fc-fused bsDbs have intrinsically high affinity because of their bivalent effects, which may explain 
these results.
Discussion
Designing non-natural antibody formats is a practical method for developing highly functional next-generation 
antibody drugs, particularly for improving the therapeutic efficacy for cancer treatments. One important 
approach is the construction of bsAbs that simultaneously bind two different targets. This cross-linking can 
be applied to several therapeutic strategies for the treatment of cancer20; however, most bsAbs that have been 
designed redirect some effector cells mainly T cells toward cancer cells. BsAbs were the first non-natural antibody 
formats approved by the FDA; however, to date only one has been approved for the treatment of cancer. To accel-
erate the development of bsAb drugs, we studied the design of functional bsAbs.
Figure 4. In vivo antitumor effects of bispecific diabodies (bsDbs). The mixture of 1.0 × 107 T-LAK cells and 
5 × 106 TFK-1 cells was injected subcutaneously into the dorsal thoracic wall of female, 6-week-old severe 
combined immunodeficient (SCID) mice. Then, five mice per group were treated intravenously with bsAb or 
PBS at the indicated doses starting at 1 h after TFK-1 inoculation, and treatment was repeated once daily for 3 
consecutive days. Data are shown as the median tumor volume (bar, SEM) in each treatment group. *Significant 
(P < 0.05) difference between PBS and 0.2 µg of LH-2HH11-2L1 or 0.2 µg of E2x3-LH (A), PBS and 0.2 µg of 
LH-2HH11 or 0.2 µg of LH-2HH11-2L6 (B), PBS and 0.02 µg of LH-HY52W tetramer (C). Statistical analysis 
was carried out using the two-way ANOVA test.
Figure 5. In vivo antitumor effects of Fc-fused bispecific diabodies (bsDbs). The mixture of 1.0 × 107 T-LAK 
cells and 5 × 106 TFK-1 cells was injected subcutaneously into the dorsal thoracic wall of female, 6-week-old 
severe combined immunodeficient (SCID) mice. Then, five mice per group were treated intravenously with 
bsAb or PBS at the indicated doses starting at 1 h after TFK-1 inoculation, and treatment was repeated once 
daily for 3 consecutive days. Data are shown as the median tumor volume (bar, SEM) in each treatment group. 
*Significant (P < 0.05) difference between PBS and Fc-LH or Fc-LH-HY52W (A). Statistical analysis was 
carried out using the two-way ANOVA test.
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In the present study, to construct highly functional bsAbs, we integrated high-affinity mutants previously 
isolated by phage display17,18 into a series of hEx3 bsAbs with specificity for EGFR and CD311–15. Increased 
affinity was observed in LH-HY52W, resulting in cytotoxic enhancements in vitro, as expected (Table 1 and 
Fig. 2A), However, further increases in cytotoxicity were not observed for other hEx3-LH mutants, LH-2HH11, 
-2HH11-2L1, and -2HH11-2L6 (Table 1 and Fig. 2B,C). These mutants were selected in the form of Fv and 
showed higher affinity than HY52W17,18. The HY52W mutation may be critical for increasing the interaction 
between h528 Fv and EGFR and additional mutations may contribute specifically to the Fv form by stabilizing the 
VH and VL interactions. To further improve hEx3-LH, direct selection using the diabody form may be effective21.
In Fc-fused hEx3-Dbs, introduction of the HY52W mutation was also effective in increasing cytotoxicity 
(Fig. 3A). As observed with hEx3-LH, the effects were not enhanced by incorporating additional mutations, 
Fc-LH-2HH11-2L1 and -2HH11-2L6, although Fc-LH-2HH11 showed slightly greater effects than -HY52W. 
However, in in vivo tumor models, the cytotoxic effects of all mutants were comparable to that of LH-Fc 
(Fig. 5A,B). In contrast, consistent with the in vitro results, all hEx3-LH mutants showed greater antitumor effects 
than hEx3-LH, but similar levels to each other. Fc fusion has intrinsically high affinity because of its bivalency. We 
did not confirm the effect of introducing high-affinity mutations into the Fc fusion in vivo, and a more sensitive 
in vivo model is needed to evaluate these high-affinity molecules.
In contrast to classic bsAbs prepared by chemical conjugation and quadroma production22–24 or Fc-fused 
bsAbs such as Fc-LH, small bsAbs may allow for greater tissue penetration and higher target retention, and can 
be produced using cost-efficient microbial expression systems25,26. Hosts such as E. coli6 and Pichia pastoris27 have 
been used to produce small bsAbs; however, clinical-grade production in these hosts remains challenging. In fact, 
blinatumomab was produced in CHO cells, i.e., a mammalian expression system. Brevibacillus choshinensis is 
an attractive protein expression host, because it is a Gram-positive bacterium that secretes proteins directly into 
culture, shows low extracellular protease activity, produces no endotoxins, and is nonpathogenic28–30. Recently, we 
successfully expressed a small type of hEx3 bsAbs using B. choshinensis and demonstrated the utility of this organ-
ism as an expression host with high secretory productivity31. Thus, small bsAbs with high therapeutic potential 
are attractive candidates for the production of next-generation therapeutic antibodies.
However, the rapid blood clearance and monovalency of small bsAbs may limit their therapeutic applica-
tions; in fact, hEx3-LH mutants showed lower antitumor effects in vivo compared to LH-Fc (Figs. 4A,B, 5A,B). 
The length and amino acid composition of the linkers can be engineered to enable small bsAbs to assemble into 
multimers, such as tandem scDbs32 and bsDb tetramers33, with higher molecular weights and bivalency for target 
antigens. We also have found that hEx3 formed tetramers with high affinity and high cytotoxicity12. The mul-
timerization of small antibody fragments may lead to improved pharmacokinetics34. In this study, LH-HY52W 
tetramers exhibited the highest in vitro growth inhibition among the small bsAbs (Fig. 2D,E) and was compa-
rable to the in vivo anti-tumor effects of Fc-fused bsDbs (Figs. 4C, 5A). However, to increase the population of 
tetramers, additional engineering such as modification of the linker, similar to the modifications of the scFv 
multimer35–37, is required. bsDb tetramers are attractive molecules with high therapeutic potential.
We observed increased cytotoxicity with bsDbs in vitro and in vivo by integrating high-affinity mutants iso-
lated in the Fv form. However, the effects of affinity maturation of bsDbs were limited, particularly with the 
Fc fusion formats. Affinity maturation by directly using each bsAb format by molecular-evolutional engineer-
ing techniques such as mammalian cell display38 and yeast display39 may effectively further improve these 
high-molecular weight molecules.
Methods
Construction of expression vectors for bsDbs. We previously described the construction of bacterial 
co-expression vectors for humanized anti-EGFR × humanized anti-CD3 bsDbs (hEx3) with different domain 
orders13: pRA-hEx3-HL for hEx3-HL, in which both chimeric single-chain components are in VH–VL order; 
pRA-hEx3-LH for hEx3-LH, in which both chimeric single-chain components are in VL–VH order. We also 
described the construction of a vector for mouse anti-EGFR × humanized anti-CD3 bsDbs (E2x3) using the 
V region of the approved therapeutic antibody cetuximab19: pRA-E2x3-LH for E2x3-LH in VL–VH order. The 
parental anti-EGFR antibody clones for hEx3s and E2x3-LH were 528 and 225, respectively40.
To recover the reductions in the affinity of humanized 528, we successfully isolated the high-affinity h528 VH 
mutant HY52W and HY52W-based 2HH11 by phage display17. In the present study, for further affinity matura-
tion, the high-affinity h528 VL mutants 2L1 and 2L6 were isolated using 2HH1118, and to improve the function 
of hEx3-LH, these mutants were integrated. Bacterial co-expression vectors for hEx3-LH mutants were prepared 
by the overlap extension PCR method: pRA-LH-HY52W, pRA-LH-2HH11, pRA-LH-2HH11-2L1, and pRA-LH-
2HH11-2L6 for LH-HY52W, LH-2HH11, LH-2HH11-2L1, and LH-2HH11-2L6, respectively.
Construction of expression vectors for Fc-fused bsDbs. We previously described the construc-
tion of the mammalian expression vectors pcDNA-hEx3-scDb-3C-Fc-HL for hEx3-scDb-3C-Fc-HL14 and 
pcDNA-hEx3-scDb-3C-Fc-LH for hEx3-scDb-3C-Fc-LH15. To simplify the designations, hEx3-scDb-3C-Fc-HL 
and hEx3-scDb-3C-Fc-LH were renamed as Fc-HL and Fc-LH in this study. To improve the function of Fc-fused 
bsDbs, we also integrated high-affinity h528 mutants into them. Mammalian expression vectors for Fc-fused 
bsDbs were prepared by the overlap extension PCR method: pcDNA-Fc-HL-HY52W, pcDNA-Fc-LH-HY52W, 
pcDNA-Fc-LH-2HH11, pcDNA-Fc-LH-2HH11-2L1, and pcDNA-Fc-LH-2HH11-2L6 for Fc-HL-HY52W, 
Fc-LH-HY52W, Fc-LH-2HH11, Fc-LH-2HH11-2L1, and Fc-LH-2HH11-2L6, respectively.
Preparation of bsDbs. The bsDbs were prepared by using the bacterial expression system we described pre-
viously13. Briefly, the constructs were expressed individually in E. coli strain BL21 Star (DE3) (Life Technologies, 
Carlsbad, CA, USA) and purified from the bacterial supernatant and periplasmic fractions. The constructs were 
7Scientific RepoRtS |         (2020) 10:4913  | https://doi.org/10.1038/s41598-020-61840-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
also prepared from the intracellular soluble fraction by using BugBuster reagent (Merck KGaA, Darmstadt, 
Germany) according to the manufacturer’s instructions34. After purification by immobilized metal-affinity 
chromatography, gel filtration analysis (HiLoad Superdex 200-pg column 26/60, GE Healthcare Bio-Science, 
Piscataway, NJ, USA) was used to fractionate the dimers of each bsDb and tetramers of LH-HY52W. The column 
was equilibrated with PBS, and then purified bsDb was loaded onto the column at a flow rate of 2–2.5 mL/min.
Preparation of Fc-fused bsDbs. The methods used for expression in CHO cells and purification of 
Fc-fused bsDbs have been described previously41. Briefly, the Fc-fused bsDbs were first purified on a protein 
A column (GE Healthcare). Gel filtration analysis (HiLoad Superdex 200 pg column 26/600, GE Healthcare) 
was conducted to fractionate the monomers of each bsAb. The column was equilibrated with PBS, and protein 
A-purified bsAb was loaded onto the column at a flow rate of 2–2.5 mL/min.
Surface plasmon resonance spectroscopy. The interactions between sEGFR and bsDbs were analyzed 
by SPR spectroscopy (Biacore 2000, GE Healthcare). The methods for the expression and purification of sEGFR 
and the evaluation conditions have been described previously16,19. sEGFR was immobilized on the cells in a CM5 
sensor chip to a maximum of 1389 resonance units. BIAevaluation software (GE Healthcare) was used to analyze 
the data. Kinetic parameters were calculated by global fitting analysis assuming a 1:1 Langmuir binding model.
Cell lines. TFK-1 cells were used in the present study for consistency with our previous reports11–15,17,19. The 
TFK-1 cell line was established by our group42. TFK-1 cells were cultured in Roswell Park Memorial Institute 1640 
medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin.
In vitro killing assay. T-LAK cells were induced as described previously43. Briefly, PBMCs were cul-
tured for 48 h at a density of 2 × 106 cells/mL in medium supplemented with 100 IU/mL recombinant human 
interleukin-2 (Shionogi Pharmaceutical Co., Osaka, Japan) in a culture flask (A/S Nunc, Roskilde, Denmark) that 
was pre-coated with anti-CD3 monoclonal antibody (10 μg/mL). In vitro growth inhibition of the cancer cells 
was evaluated by MTS assay kit (CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay; Promega, 
Madison, WI, USA) as reported previously43. Basal activity of T-LAK cells changed depending on the lot of 
PBMCs. Thus, we performed MTS assay using different ratios of T-LAK cells to cancer cells for each experiment 
and indicated in the Figure legends.
In vivo tumor models. The methods used to evaluate the in vivo antitumor properties of bsAbs have been 
previously described19. The experiments and procedures involving mice were reviewed and approved by the 
Committee on Ethics in Animal Experiments of Tohoku University and were performed under the Guidelines for 
Animal Experiments of Tohoku University according to the laws and notifications of the Japanese government.
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